Bocimed Secures Tens of Millions in Funding to Enhance Service Capabilities and Expand Drug Pipeline

Recently, VCBeat (WeChat ID: VCbeat) learned that Shanghai Bocimed Pharmaceutical Technology Co., Ltd. announced the completion of a financing round, jointly invested by Shanghai Science and Technology Innovation Group and Xingfu Capital. The funds raised will be used to enhance the company's R&D capabilities and enrich its drug development pipeline.

BociMed is a pharmaceutical R&D company specializing in complex formulations and improved innovative drugs, dedicated to the development of therapies for major diseases such as cancer, cardiovascular disorders, and neuropsychiatric conditions. The company has been recognized as a Shanghai High-Tech Enterprise, a Shanghai Credit-Building Enterprise, and a Shanghai “Specialized, Refined, Differential, and Innovative” (SRDI) Enterprise, and has achieved ISO 9001 Quality Management System certification. Since its establishment in 2012, BociMed has developed over 100 proprietary technologies. In 2018, it was designated as a “Shanghai Patent Work Pilot Enterprise.” To date, the company has been granted 15 invention patents and has 46 invention patent applications pending.

In 2016, BociMed acquired Chengdu Runze Pharmaceutical Technology Development Co., Ltd., creating synergistic effects with its upstream pharmaceutical modules. The clinical expert team comprises experienced domestic and international clinical research experts from institutions such as West China Hospital of Sichuan University (where the deputy director of the Department of Laboratory Medicine also serves as a visiting researcher at the National Center for Safety Evaluation of Traditional Chinese Medicine, formerly affiliated with West China University of Medical Sciences, now Sichuan University), Kyoto Pharmaceutical University in Japan, and the Fourth Military Medical University. To date, the team has completed more than 10 full-scale pivotal clinical trials for drugs and medical devices, as well as over 50 pilot and formal bioequivalence (BE) studies.

Shanghai Bocimed Pharmaceutical Technology Co., Ltd.

Shanghai Science and Technology Venture Capital (Group) Co., Ltd. was established in August 2014 through the strategic restructuring of Shanghai Science and Technology Investment Corporation (founded in 1992) and Shanghai Venture Capital Co., Ltd. (founded in 1999). Following the restructuring, the Group has a registered capital of RMB 1.69 billion and manages assets exceeding RMB 50 billion. It operates four core functional platforms: a fund management platform, a project investment platform, a sci-tech finance platform, and a venture capital platform. As one of the state-owned venture capital institutions with the longest history, largest scale, and most comprehensive functions in Shanghai and across China, the Group serves as a key implementing entity in Shanghai’s initiative to build a science and technology innovation center with global influence.

Xingfu Capital (Xingfu Investment Management Co., Ltd.) has organically integrated equity investment with innovative investment banking services since its establishment in May 2015. Committed to being the premier partner and catalyst for Chinese entrepreneurs, Xingfu Capital focuses on identifying and supporting outstanding companies in niche sectors of China’s emerging industries to become “hidden industry champions.” With assets under management totaling billions of yuan, Xingfu Capital’s four flagship funds have invested in nearly 40 companies over the past three years. Among these, two companies have completed initial public offerings (IPOs) and listed on stock exchanges, two have achieved exit through all-cash mergers and acquisitions, 15 projects have secured follow-on financing, and more than ten projects are currently preparing for domestic and overseas IPOs as well as merger and restructuring activities.

Reprinted from: PharmCube